Fecal microbiota transplantation: in perspective - PubMed (original) (raw)
Review
Fecal microbiota transplantation: in perspective
Shaan Gupta et al. Therap Adv Gastroenterol. 2016 Mar.
Abstract
There has been increasing interest in understanding the role of the human gut microbiome to elucidate the therapeutic potential of its manipulation. Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's gut microbial composition and confer a health benefit. FMT has been used to successfully treat recurrent Clostridium difficile infection. There are preliminary indications to suggest that it may also carry therapeutic potential for other conditions such as inflammatory bowel disease, obesity, metabolic syndrome, and functional gastrointestinal disorders.
Keywords: Clostridium difficile infection; bacteriotherapy; fecal microbiota transplantation; gut microbiome; inflammatory bowel disease.
Conflict of interest statement
Conflict of interest statement: The authors declare that there is no conflict of interest.
Figures
Figure 1.
(a), (b) Schematic to indicate the events that contribute to Clostridium difficile infection: (a) the contributions of the pathogen to disease driven by reduced gut microbiota diversity; (b) how these contributions are minimized when a more diverse microbiota is present. (c), (d) Schematic to indicate the events that contribute to the proliferation of pathobionts (resident bacteria that can contribute to disease pathology under the appropriate altered environmental conditions) in the gut microbiota. The potential contribution of the gut microbiota, and the reduction of diversity in the microbiota in particular, is highlighted as a driver for disease to draw a comparison against C. difficile infection, using C. difficile infection as a model for disease caused by reduction in host gut-microbiota diversity.
Similar articles
- Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.
Mintz M, Khair S, Grewal S, LaComb JF, Park J, Channer B, Rajapakse R, Bucobo JC, Buscaglia JM, Monzur F, Chawla A, Yang J, Robertson CE, Frank DN, Li E. Mintz M, et al. PLoS One. 2018 Jan 31;13(1):e0190997. doi: 10.1371/journal.pone.0190997. eCollection 2018. PLoS One. 2018. PMID: 29385143 Free PMC article. - Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases.
Biazzo M, Deidda G. Biazzo M, et al. J Clin Med. 2022 Jul 15;11(14):4119. doi: 10.3390/jcm11144119. J Clin Med. 2022. PMID: 35887883 Free PMC article. Review. - Recurrent Clostridium difficile infection and the microbiome.
Almeida R, Gerbaba T, Petrof EO. Almeida R, et al. J Gastroenterol. 2016 Jan;51(1):1-10. doi: 10.1007/s00535-015-1099-3. Epub 2015 Jul 8. J Gastroenterol. 2016. PMID: 26153514 Review. - Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases.
Konturek PC, Haziri D, Brzozowski T, Hess T, Heyman S, Kwiecien S, Konturek SJ, Koziel J. Konturek PC, et al. J Physiol Pharmacol. 2015 Aug;66(4):483-91. J Physiol Pharmacol. 2015. PMID: 26348073 Review. - Fecal microbiota transplantation for gastrointestinal diseases.
Matsuoka K, Mizuno S, Hayashi A, Hisamatsu T, Naganuma M, Kanai T. Matsuoka K, et al. Keio J Med. 2014;63(4):69-74. doi: 10.2302/kjm.2014-0006-RE. Epub 2014 Dec 15. Keio J Med. 2014. PMID: 25500625 Review.
Cited by
- Host-Pathogen Interactions during Shiga Toxin-Producing Escherichia coli Adherence and Colonization in the Bovine Gut: A Comprehensive Review.
Edison LK, Kudva IT, Kariyawasam S. Edison LK, et al. Microorganisms. 2024 Oct 3;12(10):2009. doi: 10.3390/microorganisms12102009. Microorganisms. 2024. PMID: 39458318 Free PMC article. Review. - Harnessing the Power of the Gut Microbiome: A Review of Supplementation Therapies for Metabolic Syndrome.
Reddy N, Chiwhane A, Acharya S, Kumar S, Parepalli A, Nelakuditi M. Reddy N, et al. Cureus. 2024 Sep 18;16(9):e69682. doi: 10.7759/cureus.69682. eCollection 2024 Sep. Cureus. 2024. PMID: 39429422 Free PMC article. Review. - Global trends and collaborative networks in gut microbiota-insulin resistance research: a comprehensive bibliometric analysis (2000-2024).
Abildinova GZ, Benberin VV, Vochshenkova TA, Afshar A, Mussin NM, Kaliyev AA, Zhussupova Z, Tamadon A. Abildinova GZ, et al. Front Med (Lausanne). 2024 Aug 15;11:1452227. doi: 10.3389/fmed.2024.1452227. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39211341 Free PMC article. - The Role of Fecal Microbiota Transplantation (FMT) in the Management of Metabolic Diseases in Humans: A Narrative Review.
Zikou E, Koliaki C, Makrilakis K. Zikou E, et al. Biomedicines. 2024 Aug 16;12(8):1871. doi: 10.3390/biomedicines12081871. Biomedicines. 2024. PMID: 39200335 Free PMC article. Review. - IgA Nephropathy: Emerging Mechanisms of Disease.
Roberts LE, Williams CEC, Oni L, Barratt J, Selvaskandan H. Roberts LE, et al. Indian J Nephrol. 2024 Jul-Aug;34(4):297-309. doi: 10.25259/ijn_425_23. Epub 2024 Jun 24. Indian J Nephrol. 2024. PMID: 39156850 Free PMC article. Review.
References
- Andrews P., Borody T., Shortis N. (1995) Bacteriotherapy for chronic constipation – long term follow up. Gastroenterology 108: A563.
- Angelberger S., Reinisch W., Makristathis A., Lichtenberger C., Dejaco C., Papay P., et al. (2013) Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 108: 1620–1630. - PubMed
- Bartlett J., Gerding D. (2008) Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 46(Suppl. 1): S12–S18. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources